FrancophonIA/ELRC3.0 huggingface dataset:
English: EDURANT is not a cure for HIV infection.
Maltese: EDURANT mhuwiex kura għall-infezzjoni tal-HIV.
English: Subjects achieved virologic response (two consecutive viral loads < 50 copies/ml) and maintained it through week 48 and week 240.
Maltese: L-individwi kisbu rispons viroloġiku (żewġ ammonti virali konsekuttivi < 50 kopja/ml) u żammewh sa ġimgħa 48 u ġimgħa 240.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with rilpivirine in one or more subsets of the paediatric population in the treatment of Human Immunodeficiency Virus (HIV-1) infection (see section 4.2 for information on paediatric use).
Maltese: L-Aġenzija Ewropea dwar il-Mediċini ddifferiet l-obbligu li jiġu ppreżentati riżultati tal-istudji b' rilpivirine f'wieħed jew iktar kategoriji tal-popolazzjoni pedjatrika fit-trattament ta' infezzjoni bilVirus tal-Immunodefiċjena Umana (HIV-1) (ara sezzjoni 4.2 għal informazzjoni dwar l-użu pedjatriku).
English: The median duration of exposure for patients in the rilpivirine arm and efavirenz arm was 104.3 and 104.1 weeks, respectively.
Maltese: It-tul ta' żmien medjan ta' esponiment għal pazjenti fil-fergħa ta' rilpivirine u fil-fergħa ta' efavirenz kien ta' 104.3 u 104.1 ġimgħa, rispettivament.
English: No clinically relevant effects on fertility were seen in animal studies (see section 5.3).
Maltese: Ma dehru l-ebda effetti klinikament rilevanti fuq il-fertilità fi studji fuq l-annimali (ara sezzjoni 5.3).
English: Patients with a baseline viral load > 100,000 HIV-1 RNA copies/ml who experienced virologic failure exhibited a higher rate of treatment-emergent resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
Maltese: Pazjenti b'tagħbija virali ta' > 100,000 kopja/ml ta' RNA tal-HIV-1 fil-linja bażi li kellhom falliment viroloġiku wrew rata ogħla ta' reżistenza li feġġet minħabba l-kura għall-klassi tal-impeditur ta' reverse transcriptase mhux nucleoside (NNRTI).
English: Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co-infection had no clinically relevant effect on the exposure to rilpivirine.
Maltese: Analiżi farmakokinetika tal-popolazzjoni wriet li koinfezzjoni bil-virus tal-epatite B u/jew Ċ ma kellu l-ebda effett klinikament rilevanti fuq l-esponiment għal rilpivirine.
English: The decrease in unbound (ie, active) rilpivirine pharmacokinetic parameters during pregnancy compared to postpartum was less pronounced than for total rilpivirine.
Maltese: In-tnaqqis fil-parametri farmakokinetiċi ta' rilpivirine mhux marbut (ie, attiv) waqt it-tqala meta mqabbel ma' ta' wara l-ħlas kien anqas milli għal rilpivirine totali.
English: and 2 for efavirenz, for the tenofovir/emtricitabine, zidovudine/lamivudine, and abacavir/lamivudine regimens, respectively.
Maltese: In-numru ta' pazjenti li fallew b'mod viroloġiku u b'ġenotipi akkoppjati (linja bażi u falliment) kien ta' 71, 11, u 4 għal rilpivirine u 30, 10, u 2 għal efavirenz, għal sistemi ta' tenofovir/emtricitabine, zidovudine/lamivudine, u abacavir/lamivudine, rispettivament.
English: - Tell your doctor if you have or have had problems with your liver, including hepatitis B and/or C, and/or problems with your kidneys.
Maltese: - Għid lit-tabib tiegħek jekk inti għandek jew qatt kellek problemi bil-fwied, inkluż epatite B u/jew Ċ, u/jew problemi bil-kliewi.
English: Resistance to emtricitabine/lamivudine % (n/N)
Maltese: Ikkurati b'efavirenz Reżistenza għal emtricitabine/lamivudine % (n/N)
English: Co-administration of rilpivirine and medicinal products that inhibit CYP3A has been observed to increase the plasma concentrations of rilpivirine.
Maltese: L-għoti ta' rilpivirine flimkien ma' prodotti mediċinali li jimpedixxu CYP3A kien osservat li jżid ilkonċentrazzjonijiet ta' rilpivirine fil-plażma.
English: Site-directed NNRTI mutant virus
Maltese: Virus b'mutazzjoni mmirata lejn is-sit ta' NNRTI
English: Medicinal products that are affected by the use of rilpivirine Rilpivirine at a dose of 25 mg once daily is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
Maltese: Prodotti mediċinali li jiġu affettwati mill-użu ta' rilpivirine Rilpivirine f'doża ta' 25 mg darba kuljum x'aktarx ma jkollux effett klinikament rilevanti fuq lesponiment ta' prodotti mediċinali mmetabolizzati permezz tal-enzimi CYP.
English: The exposure to total rilpivirine after intake of rilpivirine 25 mg once daily as part of an antiretroviral regimen was lower during pregnancy (similar for the 2
Maltese: L-esponiment għal rilpivirine totali wara t-teħid ta' rilpivirine 25 mg darba kuljum bħala parti millprogramm ta' kura antiretrovirali kien inqas waqt it-tqala (simili għat-2 u t-3 trimestru) meta mqabbel ma' wara l-ħlas (ara tabella 7).
English: In cell culture
Maltese: U LUŻU
English: There were no new safety concerns identified in the Week 240 analysis of the TMC278-C213 trial in adolescents.
Maltese: Ma ġie identifikat l-ebda tħassib ġdid dwar sigurtà fl-analiżi ta' Ġimgħa 240 tal-prova TMC278-C213 fl-adolexxenti.
English: There is limited information regarding the use of EDURANT in patients with mild or moderate hepatic impairment (Child-Pugh score A or B).
Maltese: Hemm informazzjoni limitata dwar l-użu ta' EDURANT f'pazjenti b'indeboliment ħafif sa moderat tal-fwied (punteġġ A jew B ta' Child-Pugh).
English: Take the H2-receptor antagonist at least 12 hours before or at least 4 hours after EDURANT (see section 2 “Other medicines and EDURANT”).
Maltese: Ħu l-antagonist tar-riċettur H2 mill-anqas 12-il siegħa qabel jew mill-anqas 4 sigħat wara EDURANT (ara sezzjoni 2 “Mediċini oħra u EDURANT”).
English: QT prolonging medicinal products
Maltese: IL-PRODOTT MEDIĊINALI
English: 6 cells/l Percentage of subjects with: hepatitis B/C virus co-infection Percentage of patients with the following background regimens: tenofovir disoproxil fumarate plus emtricitabine zidovudine plus lamivudine abacavir plus lamivudine
Maltese: 6 ċellula/l Perċentwal ta' individwi: b'koinfezzjoni bil-virus tal-epatite B/Ċ
English: Pharmacokinetic Results of Total Rilpivirine After Administration of Rilpivirine 25 mg Once Daily as Part of an Antiretroviral Regimen, During the 2
Maltese: Riżultati Farmakokinetiċi ta' Rilpivirine Totali Wara l-Għoti ta' Rilpivirine 25 mg Darba Kuljum bħala Parti minn Programm ta' Kura Antiretrovirali, Matul it-2 Trimestru ta' Tqala, it-3 Trimestru ta' Tqala u Wara l-Ħlas
English: The pharmacokinetic data demonstrate that total exposure (AUC) to rilpivirine as a part of an antiretroviral regimen was approximately 30% lower during pregnancy compared with postpartum (6-12 weeks).
Maltese: It-tagħrif farmakokinetiku juri li l-esponiment totali (AUC) għal rilpivirine bħala parti mill-programm ta' kura antiretrovirali kien madwar 30% inqas waqt it-tqala meta mqabbel ma' wara l-ħlas (6-12-il ġimgħa).
English: Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI resistant HIV-1.
Maltese: Razez reżistenti għal rilpivirine ntgħażlu f'koltura ta' ċelluli li bdew minn HIV-1 minn oriġini differenti li jinstab fin-natura u sottotipi kif ukoll HIV-1 reżistenti għal NNRTI.
English: Rilpivirine must not be used in combination with products containing St John's wort as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3).
Maltese: Rilpivirine m'għandux jintuża flimkien ma' prodotti li fihom St John's wort minħabba li l-għoti tagħhom flimkien jista' jwassal għal telf tal-effett terapewtiku ta' rilpivirine (ara sezzjoni 4.3).
English: Film-coated tablet
Maltese: F'koltura taċ-ċelluli
English: This analysis included 690 patients in ECHO and 678 patients in THRIVE who had completed 96 weeks of treatment or discontinued earlier.
Maltese: Din l-analiżi kienet tinkludi 690 pazjent f'ECHO u 678 pazjent fi THRIVE li kienu temmew 96 ġimgħa ta' kura jew li waqfu qabel.
English: Concomitant use of EDURANT with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine.
Maltese: L-użu ta' EDURANT flimkien ma' sustanzi azole kontra lmoffa jista' jikkawża żieda filkonċentrazzjonijiet ta' rilpivirine filplażma
English: Significant decreases in rilpivirine plasma concentrations are expected.
Maltese: Huwa mistenni tnaqqis sinifikanti fil-konċentrazzjonijiet ta' rilpivirine fil-plażma.
English: 6 cells/l in patients receiving efavirenz.
Maltese: Din l-osservazzjoni kienet l-istess fil-fergħa ta' efavirenz.
English: If you take an antacid (a medicine to treat diseases related to the acid in the stomach such as aluminium / magnesium hydroxide, calcium carbonate).
Maltese: Jekk inti tieħu antaċidu (mediċina biex tikkura mard marbut mal-aċidu fl-istonku bħalma hu aluminium / magnesium hydroxide, calcium carbonate).
English: In patients with severe renal impairment or end-stage renal disease, the combination of rilpivirine with a strong CYP3A inhibitor (e.g., ritonavir-boosted HIV protease inhibitor) should only be used if the benefit outweighs the risk (see section 5.2).
Maltese: F'pazjenti b'indeboliment qawwi tal-kliewi jew mard tal-kliewi fl-aħħar stadju, ilkombinazzjoni ta' rilpivirine flimkien ma' impeditur qawwi ta' CYP3A (eż. impeditur tal-protease talHIV rinforzat b'ritonavir) għandha tintuża biss jekk il-benefiċċju jkun akbar mir-riskju (ara sezzjoni 5.2).
English: In the week 48 pooled resistance analysis from the Phase III trials, 62 (of a total of 72) virologic failures in the rilpivirine arm had resistance data at baseline and time of failure.
Maltese: III, 62 (minn total ta' 72) falliment viroloġiku fil-fergħa ta' rilpivirine kellhom dejta dwarreżistenza fil-linja bażi u fiż-żmien tal-falliment.
English: The pharmacokinetics, safety, tolerability and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, was evaluated in trial TMC278-C213, a single-arm, open-label Phase II trial in antiretroviral treatment-naïve HIV-1 infected adolescent subjects weighing at least 32 kg.
Maltese: Il-farmakokinetika, is-sigurtà, it-tollerabilità u l-effikaċja ta' rilpivirine 25 mg darba kuljum, flimkien ma' BR magħżul mill-investigatur li kien fih żewġ NRTIs, ġew ivvalutati fil-prova TMC278-C213, b'fergħa waħda, ta' Fażi
English: As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.2).
Maltese: Minħabba li rilpivirine jintrabat b'mod qawwi mal-proteini tal-plażma, x'aktarx li ma jitneħħiex b'mod sinifikanti permezz tad-dijalisi tad-demm jew tal-peritonew (ara sezzjoni 4.2).
English: Human experience of overdose with rilpivirine is limited.
Maltese: Esperjenza b'dożi eċċessivi ta' rilpivirine fil-bnedmin hija limitata.
English: However, it may not be excluded that the pharmacologically active, unbound, rilpivirine exposure is significantly increased in moderate hepatic impairment.
Maltese: Madankollu, ma jistax jiġi eskluż li l-esponiment farmakoloġikament attiv, mingħajr limiti ta' rilpivirine jiżdied b'mod sinifikanti f'indeboliment moderat tal-fwied.
English: Co-administration of rilpivirine with medicinal products that increase gastric pH may result in decreased plasma concentrations of rilpivirine which could potentially reduce the therapeutic effect of EDURANT.
Maltese: L-għoti ta' rilpivirine flimkien ma' prodotti mediċinali li jżidu l-pH tal-istonku jista' jwassal għal tnaqqis fil-konċentrazzjonijiet ta' rilpivirine fil-plażma li possibbilment jista' jnaqqas l-effett terapewtiku ta' EDURANT.
English: The greater risk of virologic failure for patients in the rilpivirine arm was observed in the first 48 weeks of these trials (see section 5.1).
Maltese: Ir-riskju akbar ta' falliment viroloġiku għall-pazjenti fil-fergħa ta' rilpivirine ġie osservat fl-ewwel 48 ġimgħa ta' dawn il-provi (ara sezzjoni 5.1).
English: All*
Maltese: Tista'
English: In the pooled analysis for ECHO and THRIVE, demographics and baseline characteristics were balanced between the rilpivirine arm and the efavirenz arm. Table 3 displays selected baseline disease characteristics of the patients in the rilpivirine and efavirenz arms.
Maltese: Fil-ġabra ta' analiżi minn ECHO u THRIVE, karatteristiċi demografiċi u fil-linja bażi ġew ibbilanċjati bejn il-fergħa ta' rilpivirine u l-fergħa ta' efavirenz.
English: There was no impact of body weight on rilpivirine pharmacokinetics in paediatric subjects in trial TMC278-C213 (33 to 93 kg), similar to what was observed in adults.
Maltese: B'xebh ma' dak li ġie osservat fl-adulti, il-piż talġisem ma kellu l-ebda impatt fuq il-farmakokinetika ta' rilpivirine f'individwi pedjatriċi fil-prova TMC278-C213 (33 to 93 kg).
English: common decreased appetite increased triglycerides (fasted)
Maltese: komuni tnaqqis fl-aptit żieda fit-triglycerides (stat ta' sawm)
English: nd
Maltese: MS
English: - clarithromycin, erythromycin (antibiotics) - cimetidine, famotidine, nizatidine, ranitidine (H2-receptor antagonists used to treat stomach or intestinal ulcers or used to relieve heartburn due to acid reflux).
Maltese: - cimetidine, famotidine, nizatidine, ranitidine (antagonisti tar-riċettur ta' H2 li jintużaw biex jiġu kkurati ulċeri fl-istonku jew fl-imsaren jew li jintużaw biex jittaffa ħruq ta' stonku minħabba rifluss ta' aċidu).
English: Response by subcategory By background NRTI
Maltese: Rispons skont is-sottokategorija Skont l-isfond NRTI
English: From the week 96 pooled resistance analysis, the resistance outcome for patients with protocol defined virological failure, and paired genotypes (baseline and failure) is shown in table 5.
Maltese: Mill-analiżi ta' reżistenza miġbura tal-ġimgħa 96, ir-riżultat ta' reżistenza għal pazjenti li fallew b'mod viroloġiku definit fi protokoll, u ġenotipi akkoppjati (linja bażi u falliment) huwa muri fittabella 5.
English: As a precautionary measure, it is preferable to avoid the use of EDURANT during pregnancy.
Maltese: Bћala prekawzjoni hu preferribli li ma jintuzax EDURANT waqt it-tqala.
English: The full EPAR for Idelvion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Idelvion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għall-Prodotti Mediċinali Orfni għal Idelvion jinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Other information about Idelvion
Maltese: Informazzjoni oħra dwar Idelvion
English: Hypersensitivity (allergic) reactions can occur rarely with Idelvion and include: swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a fast heartbeat, tightness of the chest and wheezing.
Maltese: Reazzjonijiet ta' sensittività eċċessiva (allerġiċi) jistgħu jseħħu b'mod rari b'Idelvion u jinkludu: nefħa, ħruq u tingiż fis-sit tal-injezzjoni, tertir, fwawar, raxx bil-ħakk, uġigħ ta' ras, ħorriqija, pressjoni taddemm baxxa, letarġija, dardir u rimettar, nuqqas ta' sabar, taħbit tal-qalb mgħaġġel, għafis tas-sider, u tħarħir ta' nifs.
English: This is a summary of the European public assessment report (EPAR) for Idelvion.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Idelvion.
English: Idelvion contains the active substance albutrepenonacog alfa.
Maltese: Fih is-sustanza attiva albutrepenonacog alfa.
English: In a study in 80 adults and adolescents and another study in 27 children aged less than 12 years, Idelvion was effective at preventing bleeding, with most patients experiencing no bleeding while on preventive treatment.
Maltese: Fi studju bi 80 adult u adolexxenti u studju ieħor f'27 tifel u tifla li kellhom anqas minn 12-il sena, Idelvion kien effettiv fil-prevenzjoni tal-fsada, b'ħafna mill-pazjenti ma jesperjenzawx fsada waqt li kienu fuq kura preventiva.
English: Why is Idelvion approved?
Maltese: Għaliex ġie approvat Idelvion?
English: Furthermore, Idelvion was effective in treating bleeding episodes when they did occur; around 93% of the bleeding episodes resolved with one Idelvion injection.
Maltese: Barra minn hekk, Idelvion kien effettiv fil-kura ta' episodji ta' fsada meta seħħew; madwar 93% tal-episodji ta' fsada kienu riżolti b'injezzjoni waħda ta' Idelvion.
English: The active substance in Idelvion, albutrepenonacog alfa, works in the body in the same way as human factor IX.
Maltese: Is-sustanza attiva f'Idelvion, albutrepenonacog alfa, taħdem fil-ġisem bl-istess mod bħall-fattur IX uman.
English: What are the risks associated with Idelvion?
Maltese: X'inhuma r-riskji assoċjati ma' Idelvion?
English: Because the number of patients with haemophilia B is low, the disease is considered ‘rare', and Idelvion was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 February 2010.
Maltese: Peress li n-numru ta' pazjenti li jbatu minn emofilja B huwa baxx, il-marda hija kkunsidrata ‘rari', u Idelvion ġie kklassifikat bħala ‘mediċina orfni' (mediċina li tintuża f'mard rari) fl-4 ta' Frar 2010.
English: Idelvion is available as powder and solvent that are mixed together to make a solution for injection into a vein.
Maltese: Idelvion huwa disponibbli bħala trab u solvent li jitħalltu flimkien biex jagħmlu soluzzjoni għal injezzjoni ġol-vina.
English: A risk management plan has been developed to ensure that Idelvion is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Idelvion jintuża bl-aktar mod sigur possibbli.
English: Idelvion is a medicine used to prevent and treat bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX.
Maltese: Idelvion huwa mediċina li tintuża għall-kura u l-prevenzjoni ta' fsada f'pazjenti li jbatu mill-emofilja B, disturb tad-demm li jintiret u li huwa kkaġunat minn nuqqas ta' proteina li tgħaqqad id-demm li tissejjaħ fattur IX.
English: For the full list of side effects reported with Idelvion, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Idelvion, ara l-fuljett ta' tagħrif.
English: Studies show that Idelvion is effective at preventing and treating bleeding episodes in patients with haemophilia B, and its safety is comparable to that of other factor IX products.
Maltese: L-istudji juru li Idelvion huwa effettiv għall-prevenzjoni u l-kura tal-episodji ta' fsada f'pazjenti blemofilja B u s-sigurtà tiegħu hija komparabbli ma' dik ta' prodotti tal-fattur IX oħrajn.
English: Idelvion must not be used in patients who are hypersensitive (allergic) to the active substance or other ingredients of the medicine.
Maltese: Idelvion ma għandux jintuża minn pazjenti li jbatu minn sensittività eċċessiva (allerġiċi) għas-sustanza attiva jew għal xi wieħed mis-sustanzi mhux attivi tiegħu.
English: It may harm them,
Maltese: Epatite fulminati,
English: Hafnarfjörður Iceland
Maltese: Hafnarfjörður Islanda
English: Balkanpharma-Dupnitsa AD 3 Samokovsko Shosse Str. Dupnitsa 2600
Maltese: Balkanpharma-Dupnitsa AD 3 Samokovsko Shosse Str.
English: Pregelatinised starch (derived from maize starch) Talc
Maltese: Pregelatinised starch (derivat minn maize starch) Talc
English: Dermatitis, Rash, Urticaria
Maltese: Dermatite, Raxx, Urtikarja
English: 137.5 ml (or 150 ml)*
Maltese: 137.5 ml (jew 150 ml)*
English: Oseltamivir phosphate is a pro-drug of the active metabolite (oseltamivir carboxylate).
Maltese: Oseltamivir phospate huwa pro-droga tal-metabolu attiv (oseltamivir carboxylate).
English: Pack-size 10 capsules.
Maltese: Daqs tal-pakkett ta' 10 kapsuli.
English: • Visual disturbances.
Maltese: • Disturbi fil-vista.
English: Dermatitis (including allergic and atopic dermatitis)
Maltese: (inkluż dermatite allerġika u atopika)
English: [Only applicable for outer packaging:] 2D barcode carrying the unique identifier included.
Maltese: [Applikabbli biss għall-pakkett ta' barra:] barcode 2D li jkollu l-identifikatur uniku inkluż.
English: See Section 5.2 for exposure simulation details.
Maltese: Ara Sezzjoni 5.2 għal dettalji ta' simulazzjoni tal-espożizzjoni.
English: Ebilfumin contains sodium
Maltese: Ebilfumin fih sodium
English: For dosing, see section 4.2.
Maltese: Għad-dożaġġ, ara sezzjoni 4.2.
English: In 2008, H275Y was found in > 99 % of circulating H1N1 influenza isolates in Europe.
Maltese: Fl-2008, H275Y instab f'> 99 % tal-iżolati talinfluwenza H1N1 fiċ-ċirkolazzjoni fl-Ewropa.
English: Reykjavíkurvegi 76-78 220 Hafnarfjörður Iceland
Maltese: Reykjavíkurvegur 76-78 220
English: 90 ml or 100 ml*
Maltese: 90 ml jew 100 ml*
English: • Water
Maltese: • Ilma
English: 60 ml or 75 ml*
Maltese: 60 ml jew 75 ml*
English: The proportion of patients with secondary infections in the standard dose group and double dose group was comparable (8.2% vs 5.1%).
Maltese: doża standard u l-grupp ta' doża doppja kien komparabbli (8.2% vs 5.1%).
English: Shellac Glaze-45% (20% esterified) Black iron oxide (E172) Propylene glycol (E1520) Ammonium hydroxide 28% (E527)
Maltese: Shellac Glaze -45% (20% esterifikat) Iron Oxide iswed (E172) Propylene glycol (E1520) Ammonium hydroxide 28% (E527)
English: ≤ 7 kg up to 40 ml
Maltese: ≤ 7 kg sa 40 ml
English: Immunocompromised Patients
Maltese: Pazjenti Immunokompromessi
English: Absorbed oseltamivir is primarily (> 90 %) eliminated by conversion to oseltamivir carboxylate.
Maltese: Oseltamivir li jiġi assorbit jiġi primarjament (> 90 %) eliminat billi jibidel f'oseltamivir carboxylate.
English: Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis
Maltese: Eritema multiforme, Sindrome Stevens
English: Extemporaneous formulation
Maltese: Formulazzjoni improvizzata
English: The NNT in this study was 25 (95 % CI 23 - 62).
Maltese: L-NNT f'dan l-istudju kien 25 (95 % CI 23 - 62).
English: Reykjavíkurvegi 76-78, 220 Hafnarfjörður Iceland
Maltese: Reykjavíkurvegi 76-78 220
English: The ARs listed in the tables below fall into the following categories: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), and very rare (< 1/10,000).
Maltese: (≥ 1/100 sa < 1/10 ), mhux komuni (≥ 1/1,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000), u rari ħafna (< 1/10,000).
English: For instructions on preparing the extemporaneous formulation, see section 6.6.
Maltese: Għal struzzjonijiet dwar il-preparazzjoni tal-formulazzjon improvizzata, ara sezzjoni 6.6.
English: • probenecid (used to treat gout)
Maltese: • probenecid (jintuża għat-trattament tal-gotta)
English: Prophylaxis dose (for 10 days)
Maltese: Doża ta' profilassi (għal 10 ijiem)
English: The incidence of laboratory-confirmed clinical influenza was 2.9 % (7/238) in the placebo group and 2.1 % (5/237) in the oseltamivir group (95 % CI -2.3 %4.1 %; p = 0.772).
Maltese: influwenza klinika kkonfermata fil-laboratorju kienet 2.9 % (7/238) fil-grupp tal-plaċebo u 2.1 % (5/237) fil-grupp ta' oseltamivir (95 % CI -2.3 % - 4.1 %; p = 0.772).
English: At least 75 % of an oral dose reaches the systemic circulation as the active metabolite.
Maltese: Mhux anqas minn 75 % tad-doża orali tasal fiċċirkolazzjoni sistemika bħala metabolu attiv.
English: Specifar ABEE Τηλ: +30 210 5401500
Maltese: Specifar ΑΒΕΕ Τηλ: +30 210 5401500
English: Of those, 851 children received treatment with oseltamivir suspension.
Maltese: Minn dawn, 851 tifel u tifla rċevew trattament b'suspensjoni ta' oseltamivir.
English: (Regarding neuropsychiatric disorders, see section 4.4.)
Maltese: (Rigward disturbi newropsikjatriċi, ara sezzjoni 4.4.)
English: (Note: The drug substance, oseltamivir phosphate, readily dissolves in water.
Maltese: (Nota: Is-sustanza mediċinali, oseltamivir phosphate, tinħall malajr fl-ilma.
English: • chlorpropamide (used to treat diabetes)
Maltese: • chlorpropamide (jintuża għat-trattament tad-dijabete)